You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
A nested cohort study of 6,248 early breast cancer patients treated in neoadjuvant and adjuvant chemotherapy trials investigating the prognostic value of chemotherapy-related toxicities
|
|---|---|
| Published in |
BMC Medicine, December 2015
|
| DOI | 10.1186/s12916-015-0547-5 |
| Pubmed ID | |
| Authors |
Jean E. Abraham, Louise Hiller, Leila Dorling, Anne-Laure Vallier, Janet Dunn, Sarah Bowden, Susan Ingle, Linda Jones, Richard Hardy, Christopher Twelves, Christopher J. Poole, Paul D P Pharoah, Carlos Caldas, Helena M. Earl |
| Abstract |
The relationship between chemotherapy-related toxicities and prognosis is unclear. Previous studies have examined the association of myelosuppression parameters or neuropathy with survival and reported conflicting results. This study aims to investigate 13 common chemotherapy toxicities and their association with relapse-free survival and breast cancer-specific survival. Chemotherapy-related toxicities were collected prospectively for 6,248 women with early-stage breast cancer from four randomised controlled trials (NEAT; BR9601; tAnGo; Neo-tAnGo). Cox proportional-hazards modelling was used to analyse the association between chemotherapy-related toxicities and both breast cancer-specific survival and relapse-free survival. Models included important prognostic factors and stratified by variables violating the proportional hazards assumption. Multivariable analysis identified severe neutropenia (grades ≥3) as an independent predictor of relapse-free survival (hazard ratio (HR) = 0.86; 95 % confidence interval (CI), 0.76-0.97; P = 0.02). A similar trend was seen for breast cancer-specific survival (HR = 0.87; 95 % CI, 0.75-1.01; P = 0.06). Normal/low BMI patients experienced more severe neutropenia (P = 0.008) than patients with higher BMI. Patients with fatigue (grades ≥3) showed a trend towards reduced survival (breast cancer-specific survival: HR = 1.17; 95 % CI, 0.99-1.37; P = 0.06). In the NEAT/BR9601 sub-group analysis by treatment component, this effect was statistically significant (HR = 1.61; 95 % CI, 1.13-2.30; P = 0.009). This large study shows a significant association between chemotherapy-induced neutropenia and increased survival. It also identifies a strong relationship between low/normal BMI and increased incidence of severe neutropenia. It provides evidence to support the development of neutropenia-adapted clinical trials to investigate optimal dose calculation and its impact on clinical outcome. This is important in populations where obesity may lead to sub-optimal chemotherapy doses. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 47 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 2% |
| Croatia | 1 | 2% |
| Unknown | 45 | 96% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 7 | 15% |
| Student > Bachelor | 6 | 13% |
| Researcher | 6 | 13% |
| Professor > Associate Professor | 3 | 6% |
| Student > Master | 3 | 6% |
| Other | 6 | 13% |
| Unknown | 16 | 34% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 13 | 28% |
| Biochemistry, Genetics and Molecular Biology | 6 | 13% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 6% |
| Agricultural and Biological Sciences | 3 | 6% |
| Nursing and Health Professions | 2 | 4% |
| Other | 3 | 6% |
| Unknown | 17 | 36% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 31 December 2015.
All research outputs
#20,705,128
of 23,305,591 outputs
Outputs from BMC Medicine
#3,395
of 3,507 outputs
Outputs of similar age
#332,464
of 395,205 outputs
Outputs of similar age from BMC Medicine
#51
of 51 outputs
Altmetric has tracked 23,305,591 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,507 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 43.7. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 395,205 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 51 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.